ANNOUNCEMENT FROM THE EXTRAORDINARY GENERAL MEETING OF PHARMACOLOG I UPPSALA AB ON NOVEMBER 15, 2023
Extraordinary General Meeting in Pharmacolog i Uppsala AB, reg. no. 556723-6418, (the “Company”), took place today, Wednesday, November 15, 2023, at 10.00 am at Clarion Hotell Gillet in Uppsala.
All decisions were made in accordance with the Board’s previously published proposal and with the required majority.
Decision on share capital reduction
It was resolved to reduce the Company's share capital by a maximum of SEK 11,449,591.081, however not lower than SEK 662,138.90, for allocation to non-restricted equity. After the reduction has been carried out, in accordance with the proposal, the Company's share capital will amount to SEK 662,503.42, divided into 66,250,342 shares, each share with a quota value of SEK 0.01. Provided that the required authorization is obtained, the reduction resolution is expected to be executed in January 2024.
Resolution on amendment of the articles of association
Due to the decision to reduce the share capital, it was decided that the limits of the articles of association for the share capital shall be amended in accordance with the below.
4 § Share capital
The share capital is no less than SEK 11,500,000 and no more than SEK 46,000,000.
The share capital is not less than SEK 650,000 and not more than SEK 2,600,000.
Pharmacolog provides solutions and products that enhance work efficiency and safety when preparing injectable medication. Our goal is to help prevent medication errors and ensure maximum medication efficacy when treating patients with powerful yet potentially harmful injectable drugs. Pharmacolog’s products help staff at pharmacies and hospital wards minimize the risk of errors in the compounding process. Furthermore, by verifying that drugs and narcotics used in surgery have not been tampered with, our solutions also make a vital contribution to preventing drug diversion.